CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma

PURPOSE: Sorafenib is a multi-kinase inhibitor that is used as a standard treatment for advanced hepatocellular carcinoma (HCC). However, the mechanism of sorafenib resistance in HCC is still unclear. It has been shown that CISD2 expression is related to the progression and poor prognosis of HCC. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bowen, Wei, Shibo, Yang, Liang, Peng, Xueqiang, Ma, Yingbo, Wu, Bo, Fan, Qing, Yang, Shuo, Li, Xinyu, Jin, Hongyuan, Tang, Shilei, Huang, Mingyao, Li, Hangyu, Liu, Jingang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415543/
https://www.ncbi.nlm.nih.gov/pubmed/34485112
http://dx.doi.org/10.3389/fonc.2021.657723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415543/
https://www.ncbi.nlm.nih.gov/pubmed/34485112
http://dx.doi.org/10.3389/fonc.2021.657723

Ejemplares similares